Further, uses of recombinant protein in therapies for a variety of diseases, such as diabetes, cancer, infectious diseases, hemophilia, and anemia is a major driving factor of global recombinant protein market. The research report on recombinant protein market segments the global market by product type (hormones, growth factors, cytokines, plasma protein factor, recombinant. The growth of the segment can be attributed to availability of treatment options such as recombinant factor viia (rfviia), novoseven (manufactured by novonordisk, denmark) moreover, as per a publication by hemophilia of georgia in 2013, several new rfviia products, counterparts of novoseven, were being developed by market players such as.
China japan southeast asia india global recombinant factor viii market competition by top manufacturers, with production, price, revenue (value) and market share for. China recombinant factor viii market research report 2018 global and chinese recombinant factor viii industry, 2018 market research report home life sciences medical devices report detail. This report studies recombinant non-glycosylated protein in global market, especially in north america, china, europe, southeast asia, japan and india, with production, revenue, consumption. Human coagulation factor ⅷ market recent research report in china and global - free download as pdf file (pdf), text file (txt) or read online for free.
Usd 4,00000 | global recombinant protein consumption 2016 market research report provides information about healthcare, pharma & healthcare industry the global recombinant protein consumption 2016 market research report is a professional and in-depth study on the current state of the recombinant protein market. Bleeding disorders treatment market by drug class analysis (plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants) by type analysis (hemophilia a, hemophilia b, von willebrand disease) and by regional analysis - global forecast by 2016 - 2022. Geographically, this report splits the china market into six regions, south china east china southwest china northeast china north china recombinant factor viii.
Chart sales value and market share of wyeth's recombinant human coagulation factor viii in china, 2013-2017 chart sale price of bayer's recombinant human coagulation factor viii in some chinese cities, 2017-2018. It is expected that the market scale of recombinant human coagulation factor viii in china will continue to increase from 2018 to 2022 after 2022, there is possibility that chinese companies may launch recombinant human coagulation factor viii. Notes: sales, means the sales volume of recombinant antibody revenue, means the sales value of recombinant antibody this report studies recombinant antibody in china market, focuses on the top players in china market, with capacity, production, price, revenue and market share for each manufacturer, covering. China human coagulation factor vii market by manufacturers, regions (province), type and application, forecast to 2022 a bio similar form of recombinant activated.
In 1993, recombinant factor viii was introduced into the market and this set the scene for the rise of immunoglobulins (iggs) as the dominant driver of plasma fractionation. Synopsis this report studies recombinant peptides in global market, especially in north america, china, europe, southeast asia, japan and india, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. 4 market share of major manufacturers of recombinant human coagulation factor viii in china, 2013-2017 41 market share by sales value 42 market share by sales volume. Global recombinant antihemophilic factor market research report 2018 contains historic data that spans 2013 to 2016, and then continues to forecast to 2025 that makes this report so invaluable, resources, for the leaders as well as the new entrants in the industry pune, india - september 4, 2018.
Recombinant factor ix 43 china recombinant coagulation factors sales volume and market share by type 44 china recombinant coagulation factors sales volume and. Recombinant dna market - global industry segment analysis, regional outlook, share, growth recombinant dna market 2017 to 2027 by future market insights. The global recombinant coagulation factors market has witnessed major growth over the past few years the growth of this market is mainly due to increasing number of hemophilia patients, growing diagnosis rates, and rising number of research and development on coagulation factors. This report studies recombinant factor viii in global market, especially in north america, china, europe, southeast asia, japan and india, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025 this report focuses on top manufacturers in.
Geographical scope of this report includes : north america,china,europe,southeast asia,japan,india the study focused on a complete analysis of available data as they have included factors that drove recombinant antihemophilic factor market besides challenges and restraints. Increasing focus on product developments in countries including china, india, and south korea is another major factor market drivers north america is projected to exhibit high cagr during the forecast period, due to rising efforts from manufacturers to tap growth opportunities in us and canada. The global recombinant protein market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new.
Importation of certain recombinant factor viii products by reason of infringement of any of medications to novoeight that are on the market and that are available. China recombinant protein drug industry report, 2014-2017 factor and recombinant human follicle-stimulating hormone ( rhfsh) 23 market in china. Based on hemophilia type, the global recombinant coagulation factors market can be segmented into hemophilia a and hemophilia b hemophilia a (factor viii deficiency) results from a missing or deficient protein needed for blood clotting. Recombinant chinese hamster ovary cell (cho) hepatitis b vaccine market: global opportunity analysis and industry forecast, 2017-2023 the major factor that fuels.